Latest Soleus Capital Management, L.P. Stock Portfolio

$2.47Billion– No. of Holdings #93

Soleus Capital Management, L.P. Performance:

2026 Q1: -2.29%YTD: -2.29%2025: 25.13%

Performance for 2026 Q1 is -2.29%, and YTD is -2.29%, and 2025 is 25.13%.

About Soleus Capital Management, L.P. and 13F Hedge Fund Stock Holdings

On 2026-05-14, the fund reported it's updated stock portfolio. In the 13F Holdings report, Soleus Capital Management, L.P. reported an equity portfolio of $2.5 Billions as of 31 Mar, 2026.

The top stock holdings of Soleus Capital Management, L.P. are KRYS, CELC, TGTX. The fund has invested 12.1% of it's portfolio in KRYSTAL BIOTECH INC and 5.9% of portfolio in CELCUITY INC .

The fund managers got completely rid off AMICUS THERAPEUTICS INC (FOLD), GSK PLC (GSK) and RAPT THERAPEUTICS INC (RAPT) stocks. They significantly reduced their stock positions in ORUKA THERAPEUTICS INC, RIGEL PHARMACEUTICALS INC (RIGL) and ANAPTYSBIO INC (ANAB). Soleus Capital Management, L.P. opened new stock positions in INDIVIOR PHARMACEUTICALS INC, PROGYNY INC (PGNY) and MERCK & CO INC (MRK). The fund showed a lot of confidence in some stocks as they added substantially to TANGO THERAPEUTICS INC (TNGX), VERACYTE INC (VCYT) and NATERA INC (NTRA).

Soleus Capital Management, L.P. Equity Portfolio Value

Last Reported on: 14 May, 2026

Soleus Capital Management, L.P. Annual Return Estimates Vs S&P 500

Our best estimate is that Soleus Capital Management, L.P. made a return of -2.29% in the last quarter. In trailing 12 months, it's portfolio return was 37.68%.

Performance
S&P 500

New Buys

Ticker	$ Bought
indivior pharmaceuticals inc	38,831,500
progyny inc	35,097,700
merck & co inc	24,418,900
icon plc	21,246,700
context therapeutics inc	18,243,400
vir biotechnology inc	17,937,900
xenon pharmaceuticals inc	16,979,800
travere therapeutics inc	16,221,700

New stocks bought by Soleus Capital Management, L.P.

Additions

Ticker	% Inc.
tango therapeutics inc	4,400
veracyte inc	3,099
natera inc	495
inhibrx biosciences inc	424
urogen pharma ltd	384
insulet corp	275
vericel corp	233
united therapeutics corp del	211

Additions to existing portfolio by Soleus Capital Management, L.P.

Reductions

Ticker	% Reduced
oruka therapeutics inc	-97.37
rigel pharmaceuticals inc	-96.67
anaptysbio inc	-95.56
tyra biosciences inc	-92.00
cogent biosciences inc	-91.67
zymeworks inc	-90.00
dexcom inc	-89.21
argenx se	-88.97

Soleus Capital Management, L.P. reduced stake in above stock

Sold off

Ticker	$ Sold
amicus therapeutics inc	-74,151,700
erasca inc	-8,043,240
rapt therapeutics inc	-25,876,700
calcimedica inc	-4,506,930
capricor therapeutics inc	-18,654,800
gsk plc	-31,336,600
moonlake immunotherapeutics	-5,272,000
fractyl health inc	-880,000

Soleus Capital Management, L.P. got rid off the above stocks

Sector Distribution

Soleus Capital Management, L.P. has about 89.8% of it's holdings in Healthcare sector.

Healthcare
Others

Sector	%
Healthcare	89.8
Others	9.8

Market Cap. Distribution

Soleus Capital Management, L.P. has about 16.6% of it's portfolio invested in the large-cap and mega-cap stocks.

MID-CAP
SMALL-CAP
LARGE-CAP
UNALLOCATED
MICRO-CAP

Category	%
MID-CAP	41.6
SMALL-CAP	27.2
LARGE-CAP	16.6
UNALLOCATED	9.8
MICRO-CAP	3.8

Stocks belong to which Index?

About 62.2% of the stocks held by Soleus Capital Management, L.P. either belong to S&P 500 or RUSSELL 2000 index.

RUSSELL 2000
Others
S&P 500

Index	%
RUSSELL 2000	56.1
Others	37.8
S&P 500	6.1

Top 5 Winners (%)		%
	enliven therapeutics inc	94.7 %
TNGX	tango therapeutics inc	41.8 %
TWST	twist bioscience corp	41.3 %
CCCC	c4 therapeutics inc	37.7 %
	cg oncology inc	35.2 %

Top 5 Winners ($)		$
TWST	twist bioscience corp	24.4 M
CELC	celcuity inc	22.3 M
	enliven therapeutics inc	14.9 M
UTHR	united therapeutics corp del	13.1 M
KRYS	krystal biotech inc	12.3 M

Top 5 Losers (%)		%
	beta bionics inc	-61.8 %
ORGO	organogenesis hldgs inc	-54.1 %
JSPR	jasper therapeutics inc	-48.4 %
ADGI	invivyd inc	-47.4 %
QNRX	quoin pharmaceuticals ltd	-44.4 %

Top 5 Losers ($)		$
	beta bionics inc	-70.4 M
ORGO	organogenesis hldgs inc	-28.2 M
PODD	insulet corp	-26.5 M
NVCR	novocure ltd	-19.3 M
INSP	inspire med sys inc	-17.8 M

Soleus Capital Management, L.P. Holdings Map

This heatmap illustrates the top 50 positions within the fund's portfolio.

Current Stock Holdings of Soleus Capital Management, L.P.

Soleus Capital Management, L.P. has 93 stocks in it's portfolio. About 50.3% of the portfolio is in top 10 stocks. proved to be the most loss making stock for the portfolio. TWST was the most profitable stock for Soleus Capital Management, L.P. last quarter.

Last Reported on: 14 May, 2026

Ticker	Namesorted ascending	% Portfolio	Shares Held	$ Value	Type	% Change
ACLX	arcellx inc	0.00	0.00	0.00	sold off	-100

ADGI	invivyd inc	0.41	7,708,730	10,021,300	unchanged	0.00

ALKS	alkermes plc	2.82	1,970,860	69,689,800	added	49.04

ALNY	alnylam pharmaceuticals inc	1.76	131,650	43,559,000	added	88.07

ANAB	anaptysbio inc	0.01	8,999	332,760	reduced	-95.56

ANIP	ani pharmaceuticals inc	2.56	820,243	63,076,700	added	68.69

ARGX	argenx se	0.10	3,500	2,555,880	reduced	-88.97

ARWR	arrowhead pharmaceuticals in	0.07	28,479	1,785,630	new

AVTE	jade biosciences inc	0.45	796,744	11,194,300	unchanged	0.00

AVTX	avalo therapeutics inc	0.27	441,978	6,598,730	unchanged	0.00

AXGN	axogen inc	0.91	679,170	22,500,900	reduced	-43.72

BDSX	biodesix inc	0.24	416,599	6,040,690	new

BLTE	belite bio inc	0.00	0.00	0.00	sold off	-100

BMRN	biomarin pharmaceutical inc	1.49	650,572	36,750,800	reduced	-50.71

CAPR	capricor therapeutics inc	0.00	0.00	0.00	sold off	-100

CCCC	c4 therapeutics inc	0.41	3,803,940	10,004,400	unchanged	0.00

CDTX	cidara therapeutics inc	0.00	0.00	0.00	sold off	-100

CELC	celcuity inc	5.94	1,284,380	146,599,000	reduced	-28.97

CERS	cerus corp	0.79	10,753,700	19,571,700	added	168

CGEM	cullinan therapeutics inc	0.24	410,200	5,828,940	new